References | Age | Sex | Malignancy | Agents | irAE | Days since last administration of ICI | Treatment | Outcome |
---|---|---|---|---|---|---|---|---|
Cortazar et al. [3] | 58 | M | Melanoma | Ipilimumab | TMA | 7 | Steroids, HD | Dialysis-dependent |
King et al. [14] | 68 | F | Melanoma | Ipilimumab | TTP | 22 | Steroids, PE, IVIG, RTX | Recovered |
Youssef et al. [12] | 42 | F | Renal cell carcinoma | Nivolumab + Ipilimumab | TTP | 9 | Steroids, PE | Recovered |
Honjo et al. [15] | 52 | F | Pleomorphic carcinoma of lung | Nivolumab | TTP | 14 | Steroids, MMF, CHDF | Recovered |
Lafranchi et al. [13] | 70 | M | Melanoma | Nivolumab + Ipilimumab | TTP | 18 | Steroids, PE | Died |
Hayata et al. (This case) | 68 | M | Urothelial cancer | Pembrolizumab | TMA | 21 | Steroids, PE, HD | Died |